MabThera Meets Study Primary Endpoint In Improving Disease Symptoms When Used As First Biologic Therapy In Patients With Rheumatoid Arthritis

Roche announced that their innovative drug MabThera (rituximab) can be used effectively and safely as first-line biologic therapy to improve the debilitating symptoms of rheumatoid arthritis (RA). The pivotal study, SERENE1, investigated patients suffering from RA who had an inadequate response to methotrexate (MTX) therapy, a commonly used RA drug.

More: continued here

Filed under: Arthritis on January 29th, 2008